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Abstract
Knowledge management is positioned as an enabler of ICH Q10, and the visibility and availability of
product and process knowledge across the entire pharmaceutical product lifecycle is vital to the
sustained success of an organization and to the effectiveness of an organization’s pharmaceutical
quality system as defined by ICH Q10. This paper illustrates where knowledge management has a role
to play within each product lifecycle phase. This paper goes on to further define phase-appropriate
KM methods and tools to help address these needs and create end-to-end product and process
knowledge visibility and availability.

Introduction
Developing and manufacturing medicines is a deeply scientific endeavor, and an organization’s ability
to find, apply and grow knowledge is fundamental to its sustained success. When considering the
purpose of knowledge management (KM) in the biopharmaceutical industry, the goal should be to
prospectively manage knowledge as an asset so that the best possible knowledge is available when
and where it is needed to enable patient optimal outcomes. Knowledge management can support
this ambition through enabling a highly effective pharmaceutical quality system, inclusive of riskbased decision making powered by knowledge. Knowledge management indeed is positioned as an
enabler to the pharmaceutical quality system as established in ICH Q10 [1]. The Pharmaceutical
Product Knowledge Lifecycle (PPKL) Model [2] highlights this by identifying the need for product and
process knowledge to be visible and available across the entire pharmaceutical product lifecycle.

Figure 1: The Pharmaceutical Product Knowledge Lifecycle (PPKL) Model [2]
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The need for KM during each phase of the pharmaceutical product lifecycle
To accomplish this, there are a variety of effective KM methods and tools1 available to manage
knowledge across the pharmaceutical product lifecycle [3]. Understanding the key focus of each
lifecycle phase provides an opportunity to select phase-appropriate KM methods and tools. The intent
is not to create ‘silos’ by having distinct KM methods and tools per phase, but rather to understand
the end-to-end needs to manage knowledge and to deploy relevant, fit-for-purpose KM methods and
tools embedded in the flow of work. A best-practice principle to enable effective knowledge
management is to deploy standardized KM methods and tools [3]. With standardized approaches and
thoughtful consideration of the end-to-end needs, knowledge can be managed in a very intentional,
consistent and visible manner across the product lifecycle and across products. This improved visibility
and availability of product knowledge will better enable the goals of ICH Q10 (i.e., (i) product
realization, (ii) establishing a state of control and (iii) a basis for continual improvement [1]) and form
the basis for ‘prior knowledge’ to be available in the future.
Following for each lifecycle phase in sequence is a list of illustrative knowledge-related activities and
associated description of the central role KM can play in enabling each phase.

Product Development
Considering Product Development, illustrative knowledge-related activities include:
•
•
•

Application of prior knowledge for risk assessments to determine areas of study
Development work to capture new knowledge
Ongoing risk assessment and risk control

Knowledge Management should be a key enabler to Product Development through standardized
methods and tools delivering the following:
•
•
•

Access to prior knowledge (platform technologies, other products, expertise in the company
(individuals & CoEs2), external scientific literature, prior learnings & lessons, et al.)
Capture of new knowledge during early development work (both what worked and what did
not)
The record of product development, including scientific knowledge and supporting design
choices and other decision rationale

New Product Introduction / Technology Transfer
Considering New Product Introduction / Technology Transfer, illustrative knowledge-related activities
include:
•
•
•

1
2

Application of knowledge for risk assessments
Comprehensive knowledge transfer
Opportunity to learn more about the product/process

Methods and tools are also commonly referred to as KM practices, approaches or capabilities
CoE = Center of Excellence
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•

Supporting the goal to ensure a right-first time transfer, robust process and capable receiving
site

Knowledge Management should be a key enabler to New Product Introduction / Technology Transfer
through standardized methods and tools delivering the following:
•
•
•

Access to comprehensive product and process knowledge, including development and
manufacturing history, including key decisions, learnings from failures, changes, etc.
Access to subject matter experts / personnel with process experience
Capture of new learnings including increased knowledge and understanding of
product/process, lessons learned, etc.

Commercial Manufacturing / Continuous Improvement
Considering Commercial Manufacturing / Continuous Improvement, illustrative knowledge-related
activities include:
•
•
•

Ongoing knowledge build through accumulated manufacturing experience
Lifecycle management, including planned and unplanned changes
Seek to minimize disruptions to product availability by rapid problem solving and solving
problems at root cause

Knowledge Management should be a key enabler to Commercial Manufacturing / Continuous
Improvement through standardized methods and tools delivering the following:
•
•
•

Capture of new learnings including increased knowledge and understanding of
product/process, lessons learned, etc.
Knowledge visibility and availability across the full product lifecycle (including development)
to ensure broad access to knowledge to support process monitoring, continual improvement,
change management, investigations, et al
Support for problem solving and sharing of best practices and improvements across the
supply chain and back to development organization

Product Discontinuation
Considering Product Discontinuation, illustrative knowledge-related activities include:
•
•

Knowledge transfer for archival and future access on demand
Harvesting learnings to inform 'prior knowledge'

Knowledge Management should be a key enabler to Product Discontinuation through standardized
methods and tools delivering the following:
•
•

Capture of knowledge in a complete and structured manner to allow for future access (e.g.
stability, complaints, etc.)
Capture of learnings including insights for platform knowledge and other potential 'prior
knowledge'

3
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Phase-appropriate KM methods & tools
Table 1, Phase-appropriate KM methods & tools across the pharmaceutical product lifecycle, provides
a summary of the above considerations and corresponding KM methods and tools which can be
deployed to fulfill the needs of each lifecycle phase. These methods and tools are organized by those
required for Planning & Requirements Definition, Mostly Explicit (knowledge)-based methods and
tools, Mostly Tacit (knowledge)-based methods and tools, and Enabling Elements. Table 2, Description
of KM Methods and Tools, provides a brief description for each of these methods and tools.
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Table 1: Phase-appropriate KM methods & tools across the pharmaceutical product lifecycle
KM Methods & Tools

X

Common KM elements for Technology Transfer phase

Commercial
Manufacturing /
Continuous
Improvement

Product
Discontinuation

- Knowledge transfer for archival and
future access on demand
- Harvesting learnings to inform 'prior
knowledge'

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Tacit Knowledge Retention &
Transfer Practices

Decision Rationale Capture

Expertise Location

After Action Review /
Lessons Learned

Communities of Practice

Product Knowledge Base

Platform Knowledge Base

Taxonomy & Search

Content Management

X

X

Access to subject matter experts / personnel with process
experience

X

X

X

X

Capture of new learnings including increased knowledge and
understanding of product/process, lessons learned, etc.

X
X

X

X

X

X

X
X

X

X

X

X
X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

Knowledge visibility and availability across the full product
lifecycle (including development) to ensure broad access to
knowledge to support process monitoring, continual
improvement, change management, investigations, et al

X

X

X

X

X

X

X

X

Support for problem solving and sharing of best practices and
improvements across the supply chain and back to
development organization

X

X

X

X

X

X

X

X

Capture of knowledge in a complete and structured manner to
allow for future access (e.g. stability, complaints, etc.)

X

X

X

X

X

X

X

X

X

X

X

X
X

X

X

X

X

X

X

X

X

X
X

X

Capture of learnings including insights for platform knowledge
and other potential 'prior knowledge'

X

X

X

Common KM elements for Product Discontinuation phase

X

X

X

Capture of new learnings including increased knowledge and
understanding of product/process, lessons learned, etc.

X
X

X

Access to comprehensive product and process knowledge,
including development and manufacturing history, including
key decisions, learnings from failures, changes, etc.

Common KM elements for Commercial Manufacturing phase
- Ongoing knowledge build through
accumulated manufacturing experience
- Lifecycle management, including
planned and unplanned changes
- Seek to minimize disruptions to
product availability by rapid problem
solving and solving problems at root
cause

X

X

Sponsorship, Governance,
Metrics & Other enablers

- Application of knowledge for risk
assessments
- Comprehensive knowledge transfer
- Opportunity to learn more about the
product/process
- Supporting the goal to ensure a rightfirst time transfer, robust process and
capable receiving site

X

X

Enabling elements
Knowledge-valuing culture

New Product
Introduction /
Technology
Transfer

X

Mostly Tacit-based

KM Training

Product
Development

X

Access to prior knowledge (platform technologies, other
- Application of prior knowledge for risk products, expertise in the company (individuals & CoEs),
assessments to determine areas of study external scientific literature, prior learnings & lessons, et al)
- Development work to capture new
Capture of new knowledge during early development work
knowledge
(both what worked and what didn't)
- Ongoing risk assessment and risk
The record of product development, including scientific
control
knowledge and supporting design choices and other decision
rationale

Mostly Explicit-based

KM Roles

Common KM elements for Product Development phase

Site / Functional Area
KM Plan

Note 1: Illustrative concepts, not an exhaustive listing
Note 2: References below to knowledge refer to both explicit and tacit knowledge
Note 3: Additional concepts or complexity may be introduced when when multiple entities are involved

Knowledge Transfer Plan

How Knowledge Management can provide benefit…

Product KM Plan

Areas of emphasis where
knowledge is required

Knowledge Mapping

Lifecycle Phase

KM Maturity Assessment

Planning & Requirements
Definition

X
X

X

X
X

X

X

X

X

X

X

X

X

X
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Table 2: Description of KM Methods and Tools
KM Method or Tool
Description
Planning & Requirements Definition
A means to objectively measure maturity of KM effectiveness
KM Maturity Assessment
based on various attributes such as process, culture,
technology, etc.
A structured means to document the knowledge needed for a
Knowledge Mapping
business process, a functional group, a role, etc. Used to
understand knowledge requirements and identify gaps.
A strategy document to define the plan for how the
Product KM Plan
knowledge associated with a product will be managed.
A strategy document to define the plan for how the
Knowledge Transfer Plan
knowledge transfer will be managed.
A strategy document to define the plan for how the
Site / Functional Area KM Plan
knowledge associated with a site or functional group will be
managed.
Mostly Explicit-based
A structured3 means to manage documents and other explicit
knowledge (e.g., videos, pictures, etc.). Typically includes the
Content Management
end-to-end lifecycle of content (e.g., creation, tagging,
storage, delivery). Applies to both GMP and non-GMP content
which may be managed in separate systems.
Taxonomy is a structured means to describe and tag content
(and potentially other features such as synonyms, semantics,
Taxonomy & Search
etc.), and a means to deliver results through a robust,
integrated search enabled by such a taxonomy.
A structured means to define the scope of platform knowledge
(explicit and tacit) and corresponding approaches to manage
Platform Knowledge Base
this in a consistent way to ensure knowledge visibility and
availability across the product lifecycle.
A structured means to define the scope of product knowledge
(explicit and tacit) and corresponding approaches to manage
Product Knowledge Base
this in a consistent way to ensure knowledge visibility and
availability across the product lifecycle.
Mostly Tacit-based
A structured means to connect groups of people with a shared
Communities of Practice
need or interest
A structured means to surface learnings from the experiences
After Action Review / Lessons
of people, often associated with a project or other business
Learned
process, and subsequently capture and implement these
learnings to support continual improvement.
A structured means to identify important expertise and/or
Expertise Location
experience in the organization and connect to it on demand.
A structured means to capture decision rationale and ensure it
Decision Rationale Capture
is available in the future when needed.

3

Structured = Standardized and inclusive of people, process, technology and governance

https://arrow.tudublin.ie/level3/vol15/iss2/22
DOI: https://doi.org/10.21427/g35t-6g36

6
6

Lipa and Kane: KM Methods across the Pharmaceutical Product Lifecycle

KM Method or Tool
Tacit Knowledge Retention &
Transfer Practices

Description
A variety of structured means to identify, prioritize, transfer
and retain tacit knowledge (i.e., know-how and other
knowledge “in people’s heads”)

Enabling Elements
KM Roles
KM Training
Knowledge-valuing culture
Sponsorship, Governance,
Metrics & Other enablers

Standardized roles for managing knowledge consistently, such
as community stewards.
Training on appropriate KM topics to build awareness and
competency of individuals in the organization.
Mindsets and behaviors which value the knowledge of the
organization as an asset (e.g., capturing and sharing lessons,
seeking to leverage prior knowledge)
Best practices to enable effective and sustainable KM. [ref]

Conclusion
While there is no “one right answer” on how to best manage knowledge across the pharmaceutical
product lifecycle, a pragmatic approach to understand the intent and focus of each phase can provide
valuable insights on how knowledge might be utilized and how KM can address these needs. This
paper provides a high-level outline to illustrate this, and subsequent effort can be undertaken to
further define the specific requirements (what processes, what knowledge, what users, etc.). In fact,
the Planning & Requirements Definition section provides the impetus to do just this – to leverage such
approaches to create an intentional plan (e.g., product, site or knowledge transfer plans) supported
by a clear definition of the knowledge needed (provided by a knowledge map). The authors hope that
while this is described at a high-level in this paper, the concepts will be useful to further “demystify”
what can be done to make progress in knowledge management in support of ICH Q10 and overall
operational effectiveness.
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